Skip to content
Head to head

uniQure NV vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: QURE · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

QURE -36.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
QUREVRTX
Snapshot
Sector--Biotechnology
Last price19.35515.02
Change today-4.35%-1.08%
1-year return-30.6%+22.0%
Market cap$1.36B$130.58B
52-week range8.73 – 51.72412.27 – 568.67
Valuation
P/E (TTM)-5.5133.14
P/E percentile, own 5-yr range26th99th
P/B4.616.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.4615.32
Net profit (TTM)$-242.68M$3.88B
Revenue (TTM)$20.17M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+40.4%+11.8%
Gross margin93.9%85.5%
Operating margin-964.5%33.1%
Net margin-1154.8%30.7%
Free cash flow (TTM)$-192.96M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership97.7%96.8%
Insider activity (12mo)18 buy / 32 sell28 buy / 22 sell
Short interest (% of float)12.3%1.9%
Analyst consensus80% buy / 20% hold (10)95% buy / 5% hold (21)
Analyst price target$54 (+181%)$624 (+21%)
StockVane view
StockVane Quant RatingE (14)C (68)
Company
Employees2216,400
Founded19981989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.